Jehle J, Ficker E, Wan X, Deschenes I, Kisselbach J, Wiedmann F, Staudacher I, Schmidt C, Schweizer PA, Becker R, Katus HA, and Thomas D
Br J Pharmacol 168(5):1215-29
Publication Date: February 21, 2013
Product Type: iCell Cardiomyocytes
iCell Cardiomyocytes exhibited prolongation of cardiac action potential duration in response to zolpidem, a short-acting hypnotic drug prescribed to treat insomnia that has been clinically associated with acquired long QT syndrome (LQTS) and torsade de pointes (TdP).
iCell Cardiomyocytes treated with a known toxic drug compound showed biochemical responses that mimic toxic responses observed in the clinic, demonstrating that iCell Cardiomyocytes are a relevant in vitro model to predict human cardiotoxicity.